Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1

被引:103
|
作者
Lee, Ki Won
Kang, Nam Joo
Rogozin, Evgeny A.
Kim, Hong-Gyum
Cho, Yong Yeon
Bode, Ann M.
Lee, Hyong Joo
Surh, Young-Joon
Bowden, G. Tim
Dong, Zigang
机构
[1] Univ Minnesota, Hormel Inst, Austin, MN 55912 USA
[2] Konkuk Univ, Dept Biosci & Biotechnol, Seoul 143701, South Korea
[3] Konkuk Univ, Inst Biomed Sci & Technol, Seoul 143701, South Korea
[4] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea
[5] Seoul Natl Univ, Sch Agr Biotechnol, Seoul 151742, South Korea
[6] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85724 USA
关键词
D O I
10.1093/carcin/bgm110
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Evidence suggests that mitogen-activated protein kinase kinase (MEK) plays a role in cell transformation and tumor development and might be a significant target for chemoprevention. 3,5,4' Trihydroxytrans-stilbene (resveratrol), a non-flavonoid polyphenol found in various foods and beverages, including red wines, is reported to be a natural chemopreventive agent. However, the concentrations required to exert these effects might be difficult to achieve by drinking only one or two glasses of red wine a day. On the other hand, the flavonol content of red wine is similar to 30 times higher than that of resveratrol. Here we demonstrated that 3,3',4',5,5',7-hexahydroxyflavone (myricetin), one of the major flavonols in red wine, is a novel inhibitor of MEK1 activity and transformation of JB6 P+ mouse epidermal cells. Myricetin (10 mu M) inhibited 12-O-tetradecanoylphorbol-13-acetate (TPA) or epidermal growth factor (EGF)-induced cell transformation by 76 or 72%, respectively, compared with respective reductions of 26 or 19% by resveratrol (20 mu M). A combination of myricetin and resveratrol exerted additive but not synergistic effects on either TPA- or EGF- induced transformation. Myricetin, but not resveratrol, attenuated tumor promoter-induced activation of c-fos or activator protein-1. Myricetin strongly inhibited MEK1 kinase activity and suppressed TPA- or EGF- induced phosphorylation of extracellular signal-regulated kinase (ERK) or p90 ribosomal S6 kinase, downstream targets of MEK. Moreover, myricetin inhibited H-Ras-induced cell transformation more effectively than either PD098059, a MEK inhibitor, or resveratrol. Myricetin directly bound with glutathione S-transferase-MEK1 but did not compete with ATP. Overall, these results indicated that myricetin has potent anticancer-promoting activity and mainly targets MEK signaling, which may contribute to the chemopreventive potential of several foods including red wines.
引用
收藏
页码:1918 / 1927
页数:10
相关论文
共 50 条
  • [1] An analysis of Mek1 signaling in cell proliferation and transformation
    Greulich, H
    Erikson, RL
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (21) : 13280 - 13288
  • [2] The Use of a Chemical Biology in the Development of a Novel MEK1/2 Inhibitor
    Yoshida, Takayuki
    Yamaguchi, Takayuki
    Kawasaki, Hisashi
    Sakamoto, Shinji
    JOURNAL OF SYNTHETIC ORGANIC CHEMISTRY JAPAN, 2016, 74 (05) : 462 - 468
  • [3] MEK Inhibitor for Gastric Cancer with MEK1 Gene Mutations
    Sogabe, Shunsuke
    Togashi, Yosuke
    Kato, Hiroaki
    Kogita, Akihiro
    Mizukami, Takuro
    Sakamoto, Yoichi
    Banno, Eri
    Terashima, Masato
    Hayashi, Hidetoshi
    de Velasco, Marco A.
    Sakai, Kazuko
    Fujita, Yoshihiko
    Tomida, Shuta
    Yasuda, Takushi
    Takeyama, Yoshifumi
    Okuno, Kiyotaka
    Nishio, Kazuto
    MOLECULAR CANCER THERAPEUTICS, 2014, 13 (12) : 3098 - 3106
  • [4] Pharmacokinetic characterization of a natural product–inspired novel MEK1 inhibitor E6201 in preclinical species
    Vipul Kumar
    Edgar L. Schuck
    Robert D. Pelletier
    Nadia Farah
    Krista B. Condon
    Meng Ye
    Christopher Rowbottom
    Belinda M. King
    Zhi-Yi Zhang
    Philip L. Saxton
    Y. Nancy Wong
    Cancer Chemotherapy and Pharmacology, 2012, 69 : 229 - 237
  • [5] Characterization of GSK1120212 a novel allosteric inhibitor of MEK1/2
    Erskine, S.
    Rominger, C.
    Zappacosta, F.
    Laquerre, S.
    Adams, J.
    Tummino, P.
    Lai, Z.
    EJC SUPPLEMENTS, 2008, 6 (12): : 44 - 45
  • [6] Identification and Characterization of a Novel Chemotype MEK Inhibitor Able to Alter the Phosphorylation State of MEK1/2
    Yoshida, Takayuki
    Kakegawa, Junya
    Yamaguchi, Takayuki
    Hantani, Yoshiji
    Okajima, Nobuyuki
    Sakai, Toshiyuki
    Watanabe, Yoshihiro
    Nakamura, Motonao
    ONCOTARGET, 2012, 3 (12) : 1533 - 1545
  • [7] Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species
    Kumar, Vipul
    Schuck, Edgar L.
    Pelletier, Robert D.
    Farah, Nadia
    Condon, Krista B.
    Ye, Meng
    Rowbottom, Christopher
    King, Belinda M.
    Zhang, Zhi-Yi
    Saxton, Philip L.
    Wong, Y. Nancy
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (01) : 229 - 237
  • [8] Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
    Nuggehally R. Srinivas
    European Journal of Drug Metabolism and Pharmacokinetics, 2018, 43 : 373 - 382
  • [9] Pharmacology of Pimasertib, A Selective MEK1/2 Inhibitor
    Srinivas, Nuggehally R.
    EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (04) : 373 - 382
  • [10] MEK1 activation by PAK: A novel mechanism
    Park, Electa R.
    Eblen, Scott T.
    Catling, Andrew D.
    CELLULAR SIGNALLING, 2007, 19 (07) : 1488 - 1496